Characterization of circulating T-, NK-, and NKT cell subsets in patients with colorectal cancer: the peripheral blood immune cell profile

ConclusionThe altered phenotype of circulating immune cell subsets in CRC and its association with clinical outcome highlight the potential use of PBMC subsets as prognostic biomarkers in CRC, thereby contributing to better insight into the role of systemic immune profiles in tumor progression.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research

Related Links:

ConclusionAge, T stage, tumor location, CEA, monocytes, LMR and ApoA1 could reflect immune cells infiltrating the tumor microenvironment of CRC.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
Publication date: 8 July 2019Source: Cancer Cell, Volume 36, Issue 1Author(s): Andrew Woolston, Khurum Khan, Georgia Spain, Louise J. Barber, Beatrice Griffiths, Reyes Gonzalez-Exposito, Lisa Hornsteiner, Marco Punta, Yatish Patil, Alice Newey, Sonia Mansukhani, Matthew N. Davies, Andrew Furness, Francesco Sclafani, Clare Peckitt, Mirta Jiménez, Kyriakos Kouvelakis, Romana Ranftl, Ruwaida Begum, Isma RanaSummaryDespite biomarker stratification, the anti-EGFR antibody cetuximab is only effective against a subgroup of colorectal cancers (CRCs). This genomic and transcriptomic analysis of the cetuximab resistance lands...
Source: Cancer Cell - Category: Cancer & Oncology Source Type: research
AbstractPurpose of ReviewImmune checkpoint inhibitors have shown very promising outcomes in the subset of metastatic colorectal cancers (CRCs) that are mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H). We reviewed the existing literature on immune checkpoint inhibitors in colorectal cancers to highlight the recent advances and future directions.Recent FindingsThe significance of immune check point inhibitors in dMMR/MSI-H metastatic CRCs has been validated by several studies employing anti-programmed death cell receptor (anti-PD1) and anti-PDL1 antibodies single agent or in combination with anti-CTL...
Source: Current Colorectal Cancer Reports - Category: Cancer & Oncology Source Type: research
Colon cancer (CC) is one of the leading causes of cancer related mortality. Research over past decades have profoundly enhanced our understanding of immunotherapy, a major clinical accomplishment, and its potential role towards treating CC. However, studies investigating the expression of these immune checkpoints, such as epithelial cell adhesion molecule (EpCAM), programmed death-1 (PD-1), and programmed death-ligand 1 (PD-L1), by peripheral blood mononuclear cells (PBMCs) is lacking. Here, high-dimensional mass cytometry (CyTOF) is used to investigate immune alterations and promising immunotherapeutic targets expression ...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
ConclusionThe results reveal the frequency of these biomarkers in different malignancies, with potential implications for PD ‐1/PD‐L1 blockade use for Chinese patients with cancer.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Publication date: Available online 2 July 2019Source: International Journal of PharmaceuticsAuthor(s): Amin Reza Nikpoor, Mahmoud Reza Jaafari, Parvin Zamani, Manouchehr Teymouri, Hamed Gouklani, Ehsan Saburi, Shahrzad Amiri Darban, Ali Badiee, Ali Bahramifar, Mahdi Fasihi-Ramandi, Ramezan Ali TaheriAbstractLiposome is one of the promising technologies for antigen delivery in cancer immunotherapies. It seems that the phospholipid content of liposomes can act as immunostimulatory molecules in cancer immunotherapy. In the present study, the immunological properties of different phospholipid content of liposomal antigen deliv...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
Autoinducer-2 of Fusobacterium nucleatum promotes macrophage M1 polarization via TNFSF9/IL-1β signaling. Int Immunopharmacol. 2019 Jul 01;74:105724 Authors: Wu J, Li K, Peng W, Li H, Li Q, Wang X, Peng Y, Tang X, Fu X Abstract The effect of Fusobacterium nucleatum (F. nucleatum) autoinducer-2 (AI-2) on the polarization of macrophages and the underlying mechanism is not known. We investigated the effect of F. nucleatum AI-2 on the migration and polarization of cultured macrophages. We further screened AI-2-interacting proteins in macrophages using a quantitative proteomics strategy, and evaluated ...
Source: International Immunopharmacology - Category: Allergy & Immunology Authors: Tags: Int Immunopharmacol Source Type: research
Authors: Chai SJ, Ahmad Zabidi MM, Gan SP, Rajadurai P, Lim PVH, Ng CC, Yap LF, Teo SH, Lim KP, Patel V, Cheong SC Abstract Nasopharyngeal carcinoma (NPC) is a highly metastatic cancer prevalent in Southern China and Southeast Asia. The current knowledge on the molecular pathogenesis of NPC is still inadequate to improve disease management. Using gene expression microarrays, we have identified the four-jointed box 1 (FJX1) gene to be upregulated in primary NPC tissues relative to nonmalignant tissues. An orthologue of human FJX1, the four-jointed (fj) gene in Drosophila and Fjx1 in mouse, has reported to be associa...
Source: Disease Markers - Category: Laboratory Medicine Tags: Dis Markers Source Type: research
ConclusionEach fractionation scheme induced different lymphoid and myeloid responses as well as various modulations of PD-L1 and TIGIT expression. Furthermore, 3x8Gy was the most effective protocol when associated with anti-PD-L1 and anti-TIGIT. This is the first study combining RT and anti-TIGIT with promising results; further studies are warranted.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
ConclusionIFN-I induces STAT3 activation to activateGzmb expression to enhance CTL effector function to suppress tumor development. Human colorectal carcinoma may use down-regulation of IFNAR1 on CTLs to suppress CTL effector function to evade host cancer immunosurveillance.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Colorectal Cancer | Immunotherapy | Study